Delivered-To: pgepnewsletter@gmail.com
Received: by 2002:a98:c004:0:b0:1eb:e128:bbe3 with SMTP id l4csp3468422eic;
        Sun, 14 Jan 2024 18:44:16 -0800 (PST)
X-Google-Smtp-Source: AGHT+IGjh6R2vAETevyA3O2rpt1XHjPba+6e02vjgB42crE5bamSnGuvddeg02SpbZ3tAaUKPURD
X-Received: by 2002:a05:622a:1a9a:b0:429:d87c:f5d0 with SMTP id s26-20020a05622a1a9a00b00429d87cf5d0mr5116527qtc.11.1705286656579;
        Sun, 14 Jan 2024 18:44:16 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1705286656; cv=none;
        d=google.com; s=arc-20160816;
        b=znCdKxuABr+OUg03OKBxuf4lrwNRYeIpvBCb+wn6PTymicnuHMbS8CCr/1cE2GbHSK
         KHDeT/ciloPORKWzCWrygH4ckYuGgTdsndfmir+WHTLoDMEh1mBrWvnKC4B6CoR8J2dc
         M3fYiahthty2eiP5hqlf5T8X9GL1IrJHDPC6P/UuVMelyQ9z6fYXnZ4WDXeGd8aK3gzX
         VsA0E1oFlF+IIyB+uSnNfG8P4L33PBlt0egm8DRrM0jP6/OSz/0rwvav2I+IKGZAGPow
         w/exutU+ccjtbZYfdLltQYR8x24VHzvvZDv54fkSZs/MsinMha7mgHGv/f2vNaWV2Npk
         fAjw==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=list-unsubscribe:to:reply-to:subject:message-id:mime-version:from
         :date:dkim-signature:dkim-signature;
        bh=L55tqz2Y6rrIO1aLbJG93lh6NSJPVeTgJjnoVhHCCnk=;
        fh=m8+yFGL9AGrkSifADXzxzWHypeMVd9MF7/kbikeN2H4=;
        b=B+ue7pkelRaWMHzo4pqABOTKqkdP1en7ZnjZwWoLzz4KQqn79NiNmPNSI0fJ4NDZqJ
         qCs7LWvBw6bcbWk3cmC37FMYsWXDgPNOnmWWRSKgKRdUO1zoMOhLHafu/vwLzbPXRUoC
         FU26iIq3GQUszAjtZF0zCXslKp3b9SkOYxwZZhzdxGv3Oz2jHAMqInviM4LcF16fwbWt
         nnB27kYtAAzlco8Muy0iDgP06P9yeAkYHFeq9pNMwkXRDJNXklX5Mj+zgp4DBYCOI+md
         rpAiJxC3B9Wz5IxNuU+uqVm108+oDZE3giuP6ozl0u2uUvKjttHnn4jPly5zp/eIr0BO
         1Nfg==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=CDaF2mPA;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=rrYAFngW;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
Return-Path: <bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org>
Received: from xtrwrkzn.outbound-mail.sendgrid.net (xtrwrkzn.outbound-mail.sendgrid.net. [167.89.81.226])
        by mx.google.com with ESMTPS id h10-20020ac87d4a000000b00429d5b3db07si4342882qtb.507.2024.01.14.18.44.16
        for <pgepnewsletter@gmail.com>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Sun, 14 Jan 2024 18:44:16 -0800 (PST)
Received-SPF: pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) client-ip=167.89.81.226;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=CDaF2mPA;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=rrYAFngW;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=isid.org;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=s1; bh=L55tqz2Y6rrIO1aLbJG93lh6NSJPVeTgJjnoVhHCCnk=;
	b=CDaF2mPAWcROxCaAjHma8D8BF8LBxbviu+eyW4bG+FdYmlPUU6FkqIxEPK9XiulphMcJ
	ExteqXDVN9vS3DfkxM9Z4KAqWTaVATI2RiCEbtFRmDjkaeQSxkjmUvHKYATDizTxhW50KM
	OB7MPbV6BmhWYVTVwf1D363QAWkiHJ42fJJhdYwIQXFdCswFMIGSHaYgQptzTwAiTZbXq9
	C+HXhT9P8Cgm48PiVj1SFPTl+lb5szJ08fK+/CPfZuLfTdUwEYCZKDcCpIa5xLR5x3aXCx
	eMfcyyt5Y7i1Pq1sx3CM2uHCGtqTvk6wBO7kz90gwti4cMJ4vh+JV50/OXPKNdcg==
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=smtpapi; bh=L55tqz2Y6rrIO1aLbJG93lh6NSJPVeTgJjnoVhHCCnk=;
	b=rrYAFngW95gUV04Vt/EjJtpghH4Ueil66b3tLH6QZ0r1yI4+jzlmwXKDpRrNvMmLSezW
	iHgGgb7hMv8iZLjOviFpfmrKB3es1itTTw/no8KdInJuyPFzSWoPGzngf1STgrTJMXpWZH
	VUzP5wX+Cf72CVilkk8aoj67RY/DumSBg=
Received: by filterdrecv-776574fcdb-ts5d2 with SMTP id filterdrecv-776574fcdb-ts5d2-1-65A49BFC-2F
        2024-01-15 02:44:12.387396751 +0000 UTC m=+7718552.915197499
Received: from MTkyNjg2NjI (unknown)
	by geopod-ismtpd-19 (SG) with HTTP
	id LyTzBmW1TUWiwGtHvlh2gw
	Mon, 15 Jan 2024 02:44:12.366 +0000 (UTC)
Content-Type: multipart/alternative; boundary=d2158366cbaedbb68e23c276c250a630374bbc9876fec343b37c8787761f
Date: Mon, 15 Jan 2024 02:44:15 +0000 (UTC)
From: ProMED <promed@isid.org>
Mime-Version: 1.0
Message-ID: <LyTzBmW1TUWiwGtHvlh2gw@geopod-ismtpd-19>
Subject: PRO/EDR> Poliomyelitis update (01): Indonesia, cVDPV2
Reply-To: noreply@isid.org
X-Feedback-ID: 19268662:SG
X-SG-EID: 
 =?us-ascii?Q?lYKUi1ucKQwcfoVB1xAcbBSlsJP9QSi7ed2VWI0p5NjpCc5BQK+kujBGGO1mU1?=
 =?us-ascii?Q?iBwkNh2rR9KRnT0jSKBvcohQ9uzUQcEJk4H+dSR?=
 =?us-ascii?Q?thJHOVAv9sqN0tB4F6DOiK6xOUamBPMxFFIYbQK?=
 =?us-ascii?Q?5Bwgjq8v8PGm9SSQiOeyw0TX6oZ+C01G0sgOGwd?=
 =?us-ascii?Q?P6L605bHbZHTUnK24rpfFoo=2FwHqONYcg6OZQw9G?=
 =?us-ascii?Q?J3eyTCfaPLuq2dek1twBrBfe+Dhhm+oLNVUkBI?=
X-SG-ID: 
 =?us-ascii?Q?se=2F49CGmbS0sfR97ImeXvNhg9p9jggtUUChgqoY2wUhc93xcG=2F095a5S4+mt=2FG?=
 =?us-ascii?Q?uYUpctI=2FOGD2dwyi+uvm2j4FCdvuw0l9zcHM8iA?=
 =?us-ascii?Q?mojOvTXq7jOpDFFNtfsYkHQYACEW8pq1BXXqYmH?=
 =?us-ascii?Q?oGTsnt6QpE2ZV5WVqnpwfXWoLXx7+4YjaaUrEBi?=
 =?us-ascii?Q?DYqJ7bwx879uvi5Xta4vJ=2FSdUmUwaqErEc8nkHO?=
 =?us-ascii?Q?yNxhKCN3uWxQ46B9pvKbN1xu2ospPJePPhbVH7O?=
 =?us-ascii?Q?7Q3vPn=2FN35erWm7WzOcyE4v38+MjFF9v27wyNCp?=
 =?us-ascii?Q?xVuhjf+H3SL3RsULXtjnpm26nQPJa34PsE3LdcW?=
 =?us-ascii?Q?jsnd570wPukq5J3F=2FkF6wxcOGQfHMgjhLJq0cfi?=
 =?us-ascii?Q?dwvqAluyxQJdhPKbb5pyzHrYa0MXtWiQuJ9OFDd?=
 =?us-ascii?Q?BKvw3Q+J=2FNYy7tUv8M6PiBPQawNZ+niCJ7Lx24j?=
 =?us-ascii?Q?Pttf0GsGRJgaHo6=2FPy=2FmlK4ItGW9MG0OIIi=2FzUT?=
 =?us-ascii?Q?Sq0sARgC3AYjJ7sKpZIrWCpXf27EMxjiwWciVIJ?=
 =?us-ascii?Q?2Q=2FWQo2jI9fOFWUGzF59wRxbA4R8RkXGMIW5OdY?=
 =?us-ascii?Q?Ui0R7ltAGUq=2FFrsgW4LYLg0TBJj6iI=2Fstkm3dkJ?=
 =?us-ascii?Q?XNYTzmVGsCNcNQYXQeJUo54J6+WG2mg60Kw6RpX?=
 =?us-ascii?Q?aQAvVqZU+3t0GuBnA+uO3OacYpqy7qS334jfYg+?=
 =?us-ascii?Q?OZcH8reZA=2FqBvhvTdj30zNxSEoXMD2rifiD4z8S?=
 =?us-ascii?Q?JywehfQNeidVrTiaHKc+ksIdRrjZ4deAdx8iazA?=
 =?us-ascii?Q?wW2fZBQxTFAKOK7b70=2FmjcWQbA=3D=3D?=
To: pgepnewsletter@gmail.com
X-Entity-ID: 3CKJgmVGbBVD214dsRqreg==
List-Unsubscribe: 
 =?us-ascii?Q?=3Cmailto=3Aunsubscribe=40em7004=2Eisid=2Eorg=3Fsubject=3D19268662=2E26zhBWx0q?=
 =?us-ascii?Q?bp8REitjFB-vLrfNoZVrOdTF5CNcIAgjf5oMDAw?=
 =?us-ascii?Q?dTAwMBzm5cWR=5FN6aeIhkxD0gGDQxUoYM7FJWyRI?=
 =?us-ascii?Q?=5FOn1bmseus59-gxoAYG2IjNCDxG9DdFbvd0t30J?=
 =?us-ascii?Q?RY5PKKeMFbC0Vyp5UMkl2Vla7SVQ6JzyPJ2q1XR?=
 =?us-ascii?Q?PK=5FLpMVnCPe6vqfFw=3D=3D=2Er8x2G5zBSCHMdh1FCax?=
 =?us-ascii?Q?nHBP7jFo5n3G1rrotlfd7XptoMDAwdTAwMBTZ7Q?=
 =?us-ascii?Q?F80wpITHTjsuIkEFn3u=5FnR7ZU4iLpCnm1hthAPC?=
 =?us-ascii?Q?eJQSQb0H4nN1g9O6JY7v4Hd3Npuu6g04hZbXM-j?=
 =?us-ascii?Q?6Q18bfgmVX32KJe8Jhi81YlI8RtWdVHj=5Faj0P0v?=
 =?us-ascii?Q?-=5FKP3YSyBtHtTdttCrCcYiO7KkjRp-ebhCXBx3F?=
 =?us-ascii?Q?ALHgQWEjamk0ZHIGntRu9U=5FcGeEAKXzW13WAa26?=
 =?us-ascii?Q?FvGy-fyp-WZJwIVT87=5FWzez8NhlTEFQf7zGaMkX?=
 =?us-ascii?Q?1G3qpXCNBbBC4ANYojuD2QxSY8BkPz75NQCxcQX?=
 =?us-ascii?Q?mwwvqJjQp0vqTpvDgpG5LQP0dLQ7p3kPxVZB=5FFL?=
 =?us-ascii?Q?moGm=5FBI2mSIBeNI2fRYeKos5QwZtJsGl6wTXhE9?=
 =?us-ascii?Q?CeW2nzxoUh7BDZFb33=5FHipIe95mY-Su9NhZ34Nt?=
 =?us-ascii?Q?IsqjuLVL182Y6RrCezg34nTbpWqyG=5FtZG6Uv0Mb?=
 =?us-ascii?Q?unIIL0jPhFvMZwNV6QO8h5ZHdWJdO8jO9-HiKp3?=
 =?us-ascii?Q?Y2Ludixlm6MarrBWOuuhDBWJGs8bW4rRYtR9rNd?=
 =?us-ascii?Q?=5F7ZsrvWEMEUDwdy9-qdG=5FilCaRnZ8tH5uR5aeF4?=
 =?us-ascii?Q?=5F1vyjFs0JGkfmmhJoAYBA-EV8wZmBoKRmHRe2OR?=
 =?us-ascii?Q?XgqD3ev2xYhc2tYY2P72RPRxi1LF5QjUfOb6ghC?=
 =?us-ascii?Q?XG2sUxLY=5FvWKylwhHiCOlTXoLHAN4kiFtfrP88z?=
 =?us-ascii?Q?pBQ7fsfWylrTRxXkc8397hiIFLHJh8vK=5Fx-qWvA?=
 =?us-ascii?Q?fV2fU5NxJo96H3Buyfzi4s5Mqp0xIrSkBNnfv2Y?=
 =?us-ascii?Q?538PY=5FOWBcp5Q6Lk4KxSiThrKl0gQig6E5jSoN0?=
 =?us-ascii?Q?YRt4svUAG7IclHnvGPekLjosvA6BD3HDOjb8dQP?=
 =?us-ascii?Q?uj1kyir3DzFZep-c46UT=5FYtRVnNh9MjkFTrW6Dw?=
 =?us-ascii?Q?rrHQKplWGBbjU5-0j=5FamXD4sguOCA=5Fi7OAiiSnb?=
 =?us-ascii?Q?NkyS-fOZDODnVxmGar8Cto1NIJfwDVtF0MJ2xxN?=
 =?us-ascii?Q?AjpetVTql8N7b6GW2gtK-dkS7IzjFzC4ytGcjpM?=
 =?us-ascii?Q?ANaX1dPrMkIb5Mine-nUuAF=3E?=

--d2158366cbaedbb68e23c276c250a630374bbc9876fec343b37c8787761f
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain; charset=us-ascii
Mime-Version: 1.0

POLIOMYELITIS UPDATE (01): INDONESIA, CIRCULATING VACCINE-DERIVED
POLIOVIRUS TYPE 2
***************************************************************************=
********
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Thu 11 Jan 2024
Source: World Health Organization Disease Outbreak News [abridged,
edited]
<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON500>


Situation at a glance
---------------------
Indonesia reported 4 cases of circulating vaccine-derived poliovirus
type 2 (cVDPV2) from October 2022 to February 2023, with 3 cases
occurring in Aceh province and 1 case in West Java province. On 20 and
27 Dec 2023, the Indonesian Ministry of Health notified WHO of 2 new
confirmed cases of cVDPV2. One case, from Klaten District, Central
Java Province, is a 6-year-old female, with a history of recent travel
to Madura Island (Sampang district, East Java Province). The second
case, a 1-year-old male, is from the neighbouring district of
Pamekasan on Madura Island, East Java. Sub-optimal vaccination
coverage increases the risk of further transmission and impact on
human health. In Klaten district, where the current case is reported,
the coverage for 4 doses of bivalent oral polio vaccine (bOPV) and
inactivated polio vaccine 1 (IPV1) was at 89.8% and 88.6% respectively
in 2022. In the Pamekasan District, where the second case was
reported, the coverages for bOPV and IPV1were 88.1% and 74.1%,
respectively in 2022. In response to the new cVDPV2 cases detected in
Indonesia, several public health responses are underway. As per
protocol, detailed case investigation and risk assessment have been
conducted. Coordination across country and regional levels with the
global polio eradication initiative is ongoing. The overall risk is
assessed as high at the national level. At the regional level the
overall risk is assessed to be moderate.

Description of the situation
----------------------------
On 20 and 27 Dec 2023, the Indonesian Ministry of Health notified WHO
of 2 confirmed cases of circulating VDPV2. One case, from Klaten
district, Central Java province, is a 6-year-old female, with a
history of recent travel to Sampang district, East Java province. She
developed acute flaccid paralysis (AFP) on 21 Nov 2023 and had
previously received 2 doses of bivalent oral polio vaccine (bOPV)
through routine immunization. The case had not received any dose of
inactivated polio vaccine (IPV).

The genetic sequencing of isolates at the BioFarma National Polio
Laboratory indicates cVDPV2 with 36 nucleotide changes, genetically
linked to a case in West Java province, that was reported to WHO in
March 2023.

The second case is reported from Pamekasan district in East Java
province. The case is a 1-year-old male with an onset of paralysis on
22 Nov 2023 with a history of bOPV vaccination (4 doses) and one dose
of IPV. The sequence result indicates 43 nucleotide changes with the
Sabin 2 references.

Two environmental samples taken in Bangkalan district, East Java
province, on 7 Dec 2023, also tested positive for cVDPV2. Sequence
results showed 36 and 37 nucleotide changes.

Prior to these 2 cases of cVDPV2, in Central Java (1) and East Java
(1), 4 cases of cVDPV2 infection had been reported previously from
Indonesia. These 4 cases were reported, since 2022, in the following
locations:
- Pidie, Aceh Province in October 2022
- Aceh Utara, Aceh Province in January 2023
- Bireuen, Aceh Province in January 2023
- Purwarkarta, West Java Province in February 2023

In Central Java, the 2022 data indicate over 95% coverage for bOPV4
and IPV1 at the provincial level, in Klaten district, Central Java
province, the coverage for the 4 doses of bOPV and IPV1 was at 89.8%
and 88.6% respectively in 2022. The Pamekasan district reported
coverages of 88.1% for bOPV and 74.1% for IPV1, while the Bangkalan
district reported 69.9% for bOPV and 53.7% for IPV1.

There are no hard-to-reach areas in the region. However, sociocultural
barriers in East Java's Madura community pose challenges to
vaccination from vaccine hesitancy due to several reasons including
fear of adverse effects, multiple injections and sometimes due to
religious reasons.

Epidemiology
------------
Polio is a highly infectious disease that largely affects children
under 5 years of age, causing permanent paralysis (approximately 1 in
200 infections) or death (2-10% of those paralyzed).

The virus is transmitted from person-to-person, mainly through the
fecal-oral route or, less frequently, by contaminated water or food.
The virus multiplies in the intestine, from where it can invade the
nervous system and cause paralysis. The incubation period is usually
7-10 days but can range from 4-35 days. Up to 90% of those infected
are either asymptomatic or experience mild symptoms and the disease
usually goes unrecognized.

Vaccine-derived poliovirus is a well-documented strain of poliovirus
mutated from the strain originally contained in OPV. OPV contains a
live, weakened form of poliovirus that replicates in the intestine for
a limited period, thereby developing immunity by building up
antibodies. On rare occasions, when replicating in the
gastrointestinal tract, OPV strains can genetically change and may
spread in communities that are not fully vaccinated against polio,
especially in areas where there is poor hygiene, poor sanitation, or
overcrowding. The lower the population's immunity, the longer
vaccine-derived poliovirus survives and the more genetic changes it
undergoes.

In very rare instances, the vaccine-derived virus can genetically
change into a form that can cause paralysis as does the wild
poliovirus -- this is what is known as a vaccine-derived poliovirus
(VDPV). The detection of VDPV in at least 2 different sources and at
least 2 months apart, that are genetically linked, showing evidence of
transmission in the community, is classified as "circulating"
vaccine-derived poliovirus (cVDPV). Similar to wild poliovirus, cVDPVs
can be of 3 types (1, 2, or 3); the current outbreak in Indonesia is
due to cVDPV type 2 (cVDPV2).

Public health response
----------------------
In response to this cVDPV2 outbreak in Indonesia, several public
health responses are underway.

As per protocol, detailed case investigation and risk assessment have
been undertaken. Active case finding is being conducted in at least
200 households in both the community of the 2 current cases and
neighboring areas. Furthermore, hospital record reviews have been
performed and the identification of additional Environmental
Surveillance (ES) sites is in process.

Coordination across country and regional levels with the global polio
eradication initiative is ongoing. Efforts are ongoing to enhance and
catch up on routine immunizations, focusing especially on 2 doses of
IPV. In response to the outbreak, the government had requested the
WHO-Director General's approval for the release of novel oral polio
vaccine type 2 (nOPV2). The DG has approved the release of more than
20 million doses of nOPV2 to conduct 2 rounds of supplementary
immunization activities (SIAs) scheduled on 15 Jan 2024 and 19 Feb
2024.

Regular situation reports are being published on the WHO website and
shared with neighboring countries.

WHO risk assessment
-------------------
The overall risk is assessed as high at the national level. The
country has strong capacity to respond which was demonstrated during
the Papua cVDPV1 and Aceh and West Java cVDPV2 outbreaks. However, the
population is susceptible to type 2 polioviruses following both the
switch from trivalent OPV (tOPV) to bivalent OPV (bOPV), and the
sub-optimal IPV vaccination coverage in Central Java, East Java,
neighbouring Yogyakarta and several other provinces of Indonesia.
Vaccine hesitancy among some populations complicates vaccination
activities. There is regular population movement from Central Java,
East Java and the neighbouring populous region of Yogyakarta to other
provinces within the country and vice versa. Central Java and East
Java have moderate to strong capacity within existing resources for
implementing response measures.

At the regional level the overall risk is assessed to be moderate.
Though there is no land border from Central Java and East Java and
limited cross-border population movement from the affected area, the
virological analysis indicates that the virus may have been possibly
circulating for some time and whole genome sequencing is still
pending. This risk will be continuously assessed and will be reviewed
according to the evolution of the situation.

WHO advice
----------
It is important that all countries, in particular those with frequent
travel connections with polio-affected countries and areas, strengthen
surveillance for AFP cases in order to rapidly detect any new virus
importation and to facilitate a rapid response. Countries, territories
and areas should also maintain uniformly high routine immunization
coverage at the district level to minimize the consequences of any new
virus introduction.

WHO's International Travel and Health advice recommends that all
travellers to polio-affected areas be fully vaccinated against polio.

As per the advice of the Emergency Committee convened under the
International Health Regulations (2005), efforts to limit the
international spread of poliovirus, countries affected by poliovirus
transmission are subject to Temporary Recommendations. To comply with
the Temporary Recommendations issued under the PHEIC, any country that
have had an importation of cVDPV2 with local transmission should (i)
declare the outbreak as a national public health emergency, (ii)
encourage residents and long-term visitors to receive a dose of IPV 4
weeks to 12 months prior to international travel, (iii) ensure that
travellers who receive such vaccination have access to an appropriate
document to record their polio vaccination status, (iv) further
intensify efforts to increase IPV immunization coverage, including
sharing coverage data, and (v) intensify regional cooperation and
cross-border coordination to enhance surveillance for prompt detection
of poliovirus, and vaccinate refugees, travellers and cross-border
populations, according to the advice of the Advisory Group.

The latest epidemiological information on WPVs and cVDPVs is updated
on the website of the Global Polio Eradication Initiative a weekly
basis.

WHO advises against implementing any travel or trade restrictions
based on the current information available on this event.

--
Communicated by:
ProMED

[ProMED map:
Indonesia: <https://promedmail.org/promed-post?place=3D8714234,184>]

[See Also:
2023
----
Poliomyelitis update (37): Africa, cVDPV2 Nigeria, cVDPV1 and cVDPV2
Congo DR http://promedmail.org/post/20231214.8713703
Poliomyelitis update (36): Pakistan (KP) 6th case, sewage (WPV1)
http://promedmail.org/post/20231204.8713492
Poliomyelitis update (35): Pakistan (SD) 4th case, sewage (WPV1)
http://promedmail.org/post/20231023.8712773
Poliomyelitis update (34): Pakistan (KP) new case
http://promedmail.org/post/20231006.8712482
Poliomyelitis update (33): Afghanistan (NG) new case
http://promedmail.org/post/20230930.8712388
Poliomyelitis update (32): cVDPV1, cVDPV2, Congo DR, Pakistan, Africa
CDC http://promedmail.org/post/20230824.8711822
Poliomyelitis update (31): cVDPV1, cVDPV2, Congo DR
http://promedmail.org/post/20230810.8711632
Poliomyelitis update (30): cVDPV, Nigeria (ZA)
http://promedmail.org/post/20230810.8711629
Poliomyelitis update (29): WPV1 AFP, Pakistan, violence
http://promedmail.org/post/20230802.8711538
Poliomyelitis update (28): cVDPV2 Kenya, Tanzania, global, Pakistan,
WHO, RFI http://promedmail.org/post/20230731.8711483
Poliomyelitis update (27): AFP Malawi, AFP cVDPV2 Kenya, global, RFI
http://promedmail.org/post/20230720.8711261
Poliomyelitis update (26): WPV1 AFP Afghanistan, cVDPV1 AFP/ES, cVDPV2
AFP; vacc. http://promedmail.org/post/20230622.8710705
Poliomyelitis update (25): WPV1 AFP, cVDPV2 AFP, ES, eradication,
chronic inf http://promedmail.org/post/20230610.8710505
Poliomyelitis update (24): WPV1 AFP (Afghanistan) violence (Pakistan)
comment http://promedmail.org/post/20230604.8710402
Poliomyelitis update (23): WPV1 AFP (Afghanistan), cVDPV2 AFP (Central
African Republic), violence
http://promedmail.org/post/20230602.8710355
Poliomyelitis update (22): WPV1 AFP, WPV1 ES, cVDPV1 AFP, ES, cVDPV2
AFP, ES, RFI http://promedmail.org/post/20230526.8710248
Poliomyelitis update (21): WPV1 AFP; WPV1 ES, cVDPV1 AFP, ES; cVDPV2
AFP, ES http://promedmail.org/post/20230525.8710235
Poliomyelitis update (20): WPV1 ES, cVDPV1 AFP, cVDPV2 ES, Indonesia,
Burundi, Congo DR http://promedmail.org/post/20230422.8709635
Poliomyelitis update (19): cVDPV1 AFP; cVDPV2 AFP, ES, WPV1 SE Africa,
violence http://promedmail.org/post/20230417.8709548
Poliomyelitis update (18): Peru, add'l AFP case, cVDPV1 susp, regional
update, RFI http://promedmail.org/post/20230410.8709422
Poliomyelitis update (17): WPV1, cVDPV1&2, VDPV outbreaks 2021-2022
http://promedmail.org/post/20230407.8709373
Poliomyelitis update (16): WPV1, cVDPV1, cVDPV2, nOPV2, DRC, USA (NY)
http://promedmail.org/post/20230402.8709288
Poliomyelitis update (15): Peru, AFP cVDPV1, regional update, RFI
http://promedmail.org/post/20230325.8709148
Poliomyelitis update (14): WPV1 AFP, ES, cVDPV1 AFP, ES, cVDPV2 AFP,
ES, Indonesia, UK RFI http://promedmail.org/post/20230324.8709123
Poliomyelitis update (13): WPV1 AFP Pakistan, efficacy of bOPV booster
post IPV http://promedmail.org/post/20230319.8709028
Poliomyelitis update (12): nOPV2-assoc cVDPV2 (Burundi,DRC), WPV1 ES,
cVDPV2 AFP http://promedmail.org/post/20230317.8708985
Poliomyelitis update (11): cVDPV1 AFP, cVDPV2 AFP, Pakistan truck art,
USA alert http://promedmail.org/post/20230311.8708880
Poliomyelitis update (10): Israel, RFI, Pakistan, cVDPV1 & 2 AFP & ES
http://promedmail.org/post/20230305.8708745
Poliomyelitis update (09): Israel AFP, RFI, WPV1 ES, cVDPV1 & 2 AFP &
ES http://promedmail.org/post/20230228.8708638
Poliomyelitis update (08): WPV1 ES, cVDPV2 AFP & ES, Pakistan vacc.,
Nigeria cVDPV http://promedmail.org/post/20230209.8708270
Poliomyelitis update (07): WPV1 ES, cVDPV2 AFP & ES, lab accident,
PHEIC http://promedmail.org/post/20230206.8708199
Poliomyelitis update (06): WPV1 ES, cVDPV1 AFP, cVDPV2 ES
http://promedmail.org/post/20230128.8708021
Poliomyelitis update (05): WPV1 ES, cVDPV1 AFP, cVDPV2 AFP & ES,
Pakistan http://promedmail.org/post/20230121.8707867
Poliomyelitis update (04): cVDPV1 (Congo DR), cVDPV2 AFP (Congo DR),
ES (USA) http://promedmail.org/post/20230114.8707785
Poliomyelitis update (03): USA, wastewater cVDPV2, comment
http://promedmail.org/post/20230107.8707675
Poliomyelitis update (02): WPV1 ES, cVDPV1 AFP & ES, cVDPV2 AFP & ES,
violence http://promedmail.org/post/20230106.8707649
Poliomyelitis update (01): (Canada) VDPV2, wastewater, RFI
http://promedmail.org/post/20230102.8707576]
.................................................sb/jh/rd/jh
*##########################################################*
************************************************************
ProMED makes every effort to verify the reports that are posted, but the ac=
curacy
and completeness of the information, and of any statements or opinions base=
d
thereon, are not guaranteed. The reader assumes all risks in using informat=
ion
posted or archived by ProMED. ISID and its associated service providers sha=
ll not
be held responsible for errors or omissions or held liable for any damages =
incurred
as a result of use or reliance upon posted or archived material.
************************************************************
Donate to ProMED. Details available at: https://isid.networkforgood.com/pro=
jects/79924-invest-in-the-mission.
************************************************************
Visit ProMED's website at https://www.promedmail.org/.
Submit all items for posting via the ProMED website at https://promedmail.o=
rg/submitinfo/.
If you have any questions or need support, please contact us via the ProMED=
 website at  https://promedmail.org/support/.
You may subscribe/unsubscribe at  https://isid.org/promedmail-subscribe/.
Unsubscribe Preferences ( https://u19268662.ct.sendgrid.net/asm/?user_id=3D=
19268662&data=3DLXvVLDWaFqks7F84kVhbZv1RbgC8a-M4Gw_AZmp73XRoMDAwdTAwMG8RGa6=
HifCjMFmBa5gS5T-vQVAOto4iMtefdjS45lpmq0A7TNP3W8hF1zo--lBkaokq7sqyX7l6eoF8M4=
saL8Eia_zdvCxLKOfeespfxmWY4h9ggCdBNW8cSFRGBWlLA90K8RR4j9SKQ3h0-QHpGnNGBhw3Z=
f44By9G3xTQBGuZ_AJwBntxCPVB1bbDY-ICfpZwEmXrAMETN0cXJ-uTqybfsMDz4CWOQbLT69Fw=
CdaQB5DH6qdO2SaKiX_ohworry9VxK1qB76wYBGkTLFEa0vjZmX5vaZoyfI3B364bqAp2wSBUlO=
EXclCcxJz9cOzAkSiARe5kjurjszMUIMZ_f_gax36G6Kcy4K7WF_bLxdzISqwg0u3mPCES4Fbun=
dtHt2iwdlZlARY4zWk8xAYrvuwhyjCBo25VTHFTJzSseFo3x3WG8P59w9YVH0AYv2BxhEOhfOyC=
A-BYJIciMtiJ-cGzLMI4mpk6y1fpAdF6yh8DS_jqw0pLBD-A6RwCb_U42sRmBEEfY1Xp-mEE6dK=
oQlYZq2vclOCHaaglB_1cQACsnMHv86NpnifATf2KFNol7XMG1OVT5DBhA50GKq2HQSCFdCnsjC=
MjWbrScxkMKsIUroCbn-2w8tmWAsw7bcph26LpdkTy14bq0ZlaIRjE9wuR_Nx3Tupvdn-X9zAYz=
4oK8ItCUpnagP8dEHb3RlNiZhngdGd84Pbm8avYmd7HRTdxJTgOlQGkXjHhnt-zeY-bQl6erlj7=
ukKWTtxIz_M6iZn_KJ2dsW0Pll7-HnHscTF5Uk8C0AGxGtc7Fa8LfV8EN1-PpGZPcrG_qB3lEeP=
zU26KQoOq3CRao0r2cnOZTXkYJ1TwLEJD5y3ChDHMHPb9FQpiEtuM5rsOQnObPUlb7Qx7zlBZP_=
5ToRr-ydp6CrnF1yK6qaBF2ccwYnzA7gOe7zu9Ldpy5ZvIp65G5LPvA7vIfK5bqsColFx0kgLhE=
949xtwM_wGnIVk9aAe72Z3aCMvRAzZ_A19jMsbzfePk853P3RRxnJuAhx4iq_3zQpDugfxcGnw5=
lX4tA6ESRHAFweu-irQxgtpjetvEFi4NS3RuNtIQIeu8VCrE7LNCCzpBLJ9pqPtCex1QYIPjZFK=
bZZ4JahhE7drS9iEYRyv--1CUzhUePzpNko3yHkMqas=3D )
############################################################
############################################################

--d2158366cbaedbb68e23c276c250a630374bbc9876fec343b37c8787761f
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset=us-ascii
Mime-Version: 1.0

<!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>POLIOMYELITIS UPDATE (01): INDONESIA, CIRCULATING VACCINE-DERIVED<br>=
POLIOVIRUS TYPE 2<br>******************************************************=
*****************************<br>A ProMED-mail post<br><a href=3D"https://u=
19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisIijpefK5PNjW-mL-YZGnfgDO=
xU1G3gjwnPSi2Tfv3HA/430/hjaIV4s9SICUbHTyxfVmcA/h0/D1MbgxHZ2MTl2zV3eZ5E-G1Fu=
w6i-tQiNKWZSh056tI">http://www.promedmail.org</a><br>ProMED-mail is a progr=
am of the<br>International Society for Infectious Diseases<br><a href=3D"ht=
tps://u19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisCT5tpD4Upm3qyMCbc=
YSQvc/430/hjaIV4s9SICUbHTyxfVmcA/h1/nqpD1KOELd0Yf6-Ccfv0yd9ecuBF2pR0-bzsvfb=
XV-w">http://www.isid.org</a><br><br>Date: Thu 11 Jan 2024=0D<br>Source: Wo=
rld Health Organization Disease Outbreak News [abridged,<br>edited]=0D<br><=
a href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_csrC34X_iXpbYoMam14TJR=
WQAgAfOkkchsoIDvlYOX0xNTnc2w45aV0fpRAkjzxfIfz3NksblXkNYUuxIa5t0GX89XcTES77b=
1HjvSw/430/hjaIV4s9SICUbHTyxfVmcA/h2/VjyZ9NoNESZEqMOt31lfvmYHwiAOrpQjrZUlVt=
9y0RE">https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON5=
00</a>=0D<br>=0D<br>=0D<br>Situation at a glance=0D<br>--------------------=
-=0D<br>Indonesia reported 4 cases of circulating vaccine-derived polioviru=
s<br>type 2 (cVDPV2) from October 2022 to February 2023, with 3 cases<br>oc=
curring in Aceh province and 1 case in West Java province. On 20 and<br>27 =
Dec 2023, the Indonesian Ministry of Health notified WHO of 2 new<br>confir=
med cases of cVDPV2. One case, from Klaten District, Central<br>Java Provin=
ce, is a 6-year-old female, with a history of recent travel<br>to Madura Is=
land (Sampang district, East Java Province). The second<br>case, a 1-year-o=
ld male, is from the neighbouring district of<br>Pamekasan on Madura Island=
, East Java. Sub-optimal vaccination<br>coverage increases the risk of furt=
her transmission and impact on<br>human health. In Klaten district, where t=
he current case is reported,<br>the coverage for 4 doses of bivalent oral p=
olio vaccine (bOPV) and<br>inactivated polio vaccine 1 (IPV1) was at 89.8% =
and 88.6% respectively<br>in 2022. In the Pamekasan District, where the sec=
ond case was<br>reported, the coverages for bOPV and IPV1were 88.1% and 74.=
1%,<br>respectively in 2022. In response to the new cVDPV2 cases detected i=
n<br>Indonesia, several public health responses are underway. As per<br>pro=
tocol, detailed case investigation and risk assessment have been<br>conduct=
ed. Coordination across country and regional levels with the<br>global poli=
o eradication initiative is ongoing. The overall risk is<br>assessed as hig=
h at the national level. At the regional level the<br>overall risk is asses=
sed to be moderate.=0D<br>=0D<br>Description of the situation=0D<br>-------=
---------------------=0D<br>On 20 and 27 Dec 2023, the Indonesian Ministry =
of Health notified WHO<br>of 2 confirmed cases of circulating VDPV2. One ca=
se, from Klaten<br>district, Central Java province, is a 6-year-old female,=
 with a<br>history of recent travel to Sampang district, East Java province=
. She<br>developed acute flaccid paralysis (AFP) on 21 Nov 2023 and had<br>=
previously received 2 doses of bivalent oral polio vaccine (bOPV)<br>throug=
h routine immunization. The case had not received any dose of<br>inactivate=
d polio vaccine (IPV).=0D<br>=0D<br>The genetic sequencing of isolates at t=
he BioFarma National Polio<br>Laboratory indicates cVDPV2 with 36 nucleotid=
e changes, genetically<br>linked to a case in West Java province, that was =
reported to WHO in<br>March 2023.=0D<br>=0D<br>The second case is reported =
from Pamekasan district in East Java<br>province. The case is a 1-year-old =
male with an onset of paralysis on<br>22 Nov 2023 with a history of bOPV va=
ccination (4 doses) and one dose<br>of IPV. The sequence result indicates 4=
3 nucleotide changes with the<br>Sabin 2 references.=0D<br>=0D<br>Two envir=
onmental samples taken in Bangkalan district, East Java<br>province, on 7 D=
ec 2023, also tested positive for cVDPV2. Sequence<br>results showed 36 and=
 37 nucleotide changes.=0D<br>=0D<br>Prior to these 2 cases of cVDPV2, in C=
entral Java (1) and East Java<br>(1), 4 cases of cVDPV2 infection had been =
reported previously from<br>Indonesia. These 4 cases were reported, since 2=
022, in the following<br>locations:=0D<br>- Pidie, Aceh Province in October=
 2022=0D<br>- Aceh Utara, Aceh Province in January 2023=0D<br>- Bireuen, Ac=
eh Province in January 2023=0D<br>- Purwarkarta, West Java Province in Febr=
uary 2023=0D<br>=0D<br>In Central Java, the 2022 data indicate over 95% cov=
erage for bOPV4<br>and IPV1 at the provincial level, in Klaten district, Ce=
ntral Java<br>province, the coverage for the 4 doses of bOPV and IPV1 was a=
t 89.8%<br>and 88.6% respectively in 2022. The Pamekasan district reported<=
br>coverages of 88.1% for bOPV and 74.1% for IPV1, while the Bangkalan<br>d=
istrict reported 69.9% for bOPV and 53.7% for IPV1.=0D<br>=0D<br>There are =
no hard-to-reach areas in the region. However, sociocultural<br>barriers in=
 East Java's Madura community pose challenges to<br>vaccination from vaccin=
e hesitancy due to several reasons including<br>fear of adverse effects, mu=
ltiple injections and sometimes due to<br>religious reasons.=0D<br>=0D<br>E=
pidemiology=0D<br>------------=0D<br>Polio is a highly infectious disease t=
hat largely affects children<br>under 5 years of age, causing permanent par=
alysis (approximately 1 in<br>200 infections) or death (2-10% of those para=
lyzed).=0D<br>=0D<br>The virus is transmitted from person-to-person, mainly=
 through the<br>fecal-oral route or, less frequently, by contaminated water=
 or food.<br>The virus multiplies in the intestine, from where it can invad=
e the<br>nervous system and cause paralysis. The incubation period is usual=
ly<br>7-10 days but can range from 4-35 days. Up to 90% of those infected<b=
r>are either asymptomatic or experience mild symptoms and the disease<br>us=
ually goes unrecognized.=0D<br>=0D<br>Vaccine-derived poliovirus is a well-=
documented strain of poliovirus<br>mutated from the strain originally conta=
ined in OPV. OPV contains a<br>live, weakened form of poliovirus that repli=
cates in the intestine for<br>a limited period, thereby developing immunity=
 by building up<br>antibodies. On rare occasions, when replicating in the<b=
r>gastrointestinal tract, OPV strains can genetically change and may<br>spr=
ead in communities that are not fully vaccinated against polio,<br>especial=
ly in areas where there is poor hygiene, poor sanitation, or<br>overcrowdin=
g. The lower the population's immunity, the longer<br>vaccine-derived polio=
virus survives and the more genetic changes it<br>undergoes.=0D<br>=0D<br>I=
n very rare instances, the vaccine-derived virus can genetically<br>change =
into a form that can cause paralysis as does the wild<br>poliovirus -- this=
 is what is known as a vaccine-derived poliovirus<br>(VDPV). The detection =
of VDPV in at least 2 different sources and at<br>least 2 months apart, tha=
t are genetically linked, showing evidence of<br>transmission in the commun=
ity, is classified as "circulating"<br>vaccine-derived poliovirus (cVDPV). =
Similar to wild poliovirus, cVDPVs<br>can be of 3 types (1, 2, or 3); the c=
urrent outbreak in Indonesia is<br>due to cVDPV type 2 (cVDPV2).=0D<br>=0D<=
br>Public health response=0D<br>----------------------=0D<br>In response to=
 this cVDPV2 outbreak in Indonesia, several public<br>health responses are =
underway.=0D<br>=0D<br>As per protocol, detailed case investigation and ris=
k assessment have<br>been undertaken. Active case finding is being conducte=
d in at least<br>200 households in both the community of the 2 current case=
s and<br>neighboring areas. Furthermore, hospital record reviews have been<=
br>performed and the identification of additional Environmental<br>Surveill=
ance (ES) sites is in process.=0D<br>=0D<br>Coordination across country and=
 regional levels with the global polio<br>eradication initiative is ongoing=
. Efforts are ongoing to enhance and<br>catch up on routine immunizations, =
focusing especially on 2 doses of<br>IPV. In response to the outbreak, the =
government had requested the<br>WHO-Director General's approval for the rel=
ease of novel oral polio<br>vaccine type 2 (nOPV2). The DG has approved the=
 release of more than<br>20 million doses of nOPV2 to conduct 2 rounds of s=
upplementary<br>immunization activities (SIAs) scheduled on 15 Jan 2024 and=
 19 Feb<br>2024.=0D<br>=0D<br>Regular situation reports are being published=
 on the WHO website and<br>shared with neighboring countries.=0D<br>=0D<br>=
WHO risk assessment=0D<br>-------------------=0D<br>The overall risk is ass=
essed as high at the national level. The<br>country has strong capacity to =
respond which was demonstrated during<br>the Papua cVDPV1 and Aceh and West=
 Java cVDPV2 outbreaks. However, the<br>population is susceptible to type 2=
 polioviruses following both the<br>switch from trivalent OPV (tOPV) to biv=
alent OPV (bOPV), and the<br>sub-optimal IPV vaccination coverage in Centra=
l Java, East Java,<br>neighbouring Yogyakarta and several other provinces o=
f Indonesia.<br>Vaccine hesitancy among some populations complicates vaccin=
ation<br>activities. There is regular population movement from Central Java=
,<br>East Java and the neighbouring populous region of Yogyakarta to other<=
br>provinces within the country and vice versa. Central Java and East<br>Ja=
va have moderate to strong capacity within existing resources for<br>implem=
enting response measures.=0D<br>=0D<br>At the regional level the overall ri=
sk is assessed to be moderate.<br>Though there is no land border from Centr=
al Java and East Java and<br>limited cross-border population movement from =
the affected area, the<br>virological analysis indicates that the virus may=
 have been possibly<br>circulating for some time and whole genome sequencin=
g is still<br>pending. This risk will be continuously assessed and will be =
reviewed<br>according to the evolution of the situation.=0D<br>=0D<br>WHO a=
dvice=0D<br>----------=0D<br>It is important that all countries, in particu=
lar those with frequent<br>travel connections with polio-affected countries=
 and areas, strengthen<br>surveillance for AFP cases in order to rapidly de=
tect any new virus<br>importation and to facilitate a rapid response. Count=
ries, territories<br>and areas should also maintain uniformly high routine =
immunization<br>coverage at the district level to minimize the consequences=
 of any new<br>virus introduction.=0D<br>=0D<br>WHO's International Travel =
and Health advice recommends that all<br>travellers to polio-affected areas=
 be fully vaccinated against polio.=0D<br>=0D<br>As per the advice of the E=
mergency Committee convened under the<br>International Health Regulations (=
2005), efforts to limit the<br>international spread of poliovirus, countrie=
s affected by poliovirus<br>transmission are subject to Temporary Recommend=
ations. To comply with<br>the Temporary Recommendations issued under the PH=
EIC, any country that<br>have had an importation of cVDPV2 with local trans=
mission should (i)<br>declare the outbreak as a national public health emer=
gency, (ii)<br>encourage residents and long-term visitors to receive a dose=
 of IPV 4<br>weeks to 12 months prior to international travel, (iii) ensure=
 that<br>travellers who receive such vaccination have access to an appropri=
ate<br>document to record their polio vaccination status, (iv) further<br>i=
ntensify efforts to increase IPV immunization coverage, including<br>sharin=
g coverage data, and (v) intensify regional cooperation and<br>cross-border=
 coordination to enhance surveillance for prompt detection<br>of poliovirus=
, and vaccinate refugees, travellers and cross-border<br>populations, accor=
ding to the advice of the Advisory Group.=0D<br>=0D<br>The latest epidemiol=
ogical information on WPVs and cVDPVs is updated<br>on the website of the G=
lobal Polio Eradication Initiative a weekly<br>basis.=0D<br>=0D<br>WHO advi=
ses against implementing any travel or trade restrictions<br>based on the c=
urrent information available on this event.=0D<br>=0D<br>--=0D<br>Communica=
ted by:=0D<br>ProMED<br><br>[ProMED map:=0D<br>Indonesia: <a href=3D"https:=
//u19268662.ct.sendgrid.net/ss/c/sSnCkKCWBvais3EuVAOvgy2WOIX7pp1nXnn4AbwuQ3=
Z6WbkfhqXYXU-aTMPJ8yThpUZYF5yA8vF4J9D-gqP0og/430/hjaIV4s9SICUbHTyxfVmcA/h3/=
K0317KFiW-oL_TfoSEHPGj3UCphYUQGm16TBRR1s53Q">https://promedmail.org/promed-=
post?place=3D8714234,184</a>]<br><br>[See Also:<br>2023=0D<br>----=0D<br>Po=
liomyelitis update (37): Africa, cVDPV2 Nigeria, cVDPV1 and cVDPV2<br>Congo=
 DR http://promedmail.org/post/20231214.8713703=0D<br>Poliomyelitis update =
(36): Pakistan (KP) 6th case, sewage (WPV1)<br>http://promedmail.org/post/2=
0231204.8713492=0D<br>Poliomyelitis update (35): Pakistan (SD) 4th case, se=
wage (WPV1)<br>http://promedmail.org/post/20231023.8712773=0D<br>Poliomyeli=
tis update (34): Pakistan (KP) new case<br>http://promedmail.org/post/20231=
006.8712482=0D<br>Poliomyelitis update (33): Afghanistan (NG) new case<br>h=
ttp://promedmail.org/post/20230930.8712388=0D<br>Poliomyelitis update (32):=
 cVDPV1, cVDPV2, Congo DR, Pakistan, Africa<br>CDC http://promedmail.org/po=
st/20230824.8711822=0D<br>Poliomyelitis update (31): cVDPV1, cVDPV2, Congo =
DR<br>http://promedmail.org/post/20230810.8711632=0D<br>Poliomyelitis updat=
e (30): cVDPV, Nigeria (ZA)<br>http://promedmail.org/post/20230810.8711629=0D=
<br>Poliomyelitis update (29): WPV1 AFP, Pakistan, violence<br>http://prome=
dmail.org/post/20230802.8711538=0D<br>Poliomyelitis update (28): cVDPV2 Ken=
ya, Tanzania, global, Pakistan,<br>WHO, RFI http://promedmail.org/post/2023=
0731.8711483=0D<br>Poliomyelitis update (27): AFP Malawi, AFP cVDPV2 Kenya,=
 global, RFI<br>http://promedmail.org/post/20230720.8711261=0D<br>Poliomyel=
itis update (26): WPV1 AFP Afghanistan, cVDPV1 AFP/ES, cVDPV2<br>AFP; vacc.=
 http://promedmail.org/post/20230622.8710705=0D<br>Poliomyelitis update (25=
): WPV1 AFP, cVDPV2 AFP, ES, eradication,<br>chronic inf http://promedmail.=
org/post/20230610.8710505=0D<br>Poliomyelitis update (24): WPV1 AFP (Afghan=
istan) violence (Pakistan)<br>comment http://promedmail.org/post/20230604.8=
710402=0D<br>Poliomyelitis update (23): WPV1 AFP (Afghanistan), cVDPV2 AFP =
(Central<br>African Republic), violence<br>http://promedmail.org/post/20230=
602.8710355=0D<br>Poliomyelitis update (22): WPV1 AFP, WPV1 ES, cVDPV1 AFP,=
 ES, cVDPV2<br>AFP, ES, RFI http://promedmail.org/post/20230526.8710248=0D<=
br>Poliomyelitis update (21): WPV1 AFP; WPV1 ES, cVDPV1 AFP, ES; cVDPV2<br>=
AFP, ES http://promedmail.org/post/20230525.8710235=0D<br>Poliomyelitis upd=
ate (20): WPV1 ES, cVDPV1 AFP, cVDPV2 ES, Indonesia,<br>Burundi, Congo DR h=
ttp://promedmail.org/post/20230422.8709635=0D<br>Poliomyelitis update (19):=
 cVDPV1 AFP; cVDPV2 AFP, ES, WPV1 SE Africa,<br>violence http://promedmail.=
org/post/20230417.8709548=0D<br>Poliomyelitis update (18): Peru, add'l AFP =
case, cVDPV1 susp, regional<br>update, RFI http://promedmail.org/post/20230=
410.8709422=0D<br>Poliomyelitis update (17): WPV1, cVDPV1&2, VDPV outbreaks=
 2021-2022<br>http://promedmail.org/post/20230407.8709373=0D<br>Poliomyelit=
is update (16): WPV1, cVDPV1, cVDPV2, nOPV2, DRC, USA (NY)<br>http://promed=
mail.org/post/20230402.8709288=0D<br>Poliomyelitis update (15): Peru, AFP c=
VDPV1, regional update, RFI<br>http://promedmail.org/post/20230325.8709148=0D=
<br>Poliomyelitis update (14): WPV1 AFP, ES, cVDPV1 AFP, ES, cVDPV2 AFP,<br=
>ES, Indonesia, UK RFI http://promedmail.org/post/20230324.8709123=0D<br>Po=
liomyelitis update (13): WPV1 AFP Pakistan, efficacy of bOPV booster<br>pos=
t IPV http://promedmail.org/post/20230319.8709028=0D<br>Poliomyelitis updat=
e (12): nOPV2-assoc cVDPV2 (Burundi,DRC), WPV1 ES,<br>cVDPV2 AFP http://pro=
medmail.org/post/20230317.8708985=0D<br>Poliomyelitis update (11): cVDPV1 A=
FP, cVDPV2 AFP, Pakistan truck art,<br>USA alert http://promedmail.org/post=
/20230311.8708880=0D<br>Poliomyelitis update (10): Israel, RFI, Pakistan, c=
VDPV1 & 2 AFP & ES<br>http://promedmail.org/post/20230305.8708745=0D<br>Pol=
iomyelitis update (09): Israel AFP, RFI, WPV1 ES, cVDPV1 & 2 AFP &<br>ES ht=
tp://promedmail.org/post/20230228.8708638=0D<br>Poliomyelitis update (08): =
WPV1 ES, cVDPV2 AFP & ES, Pakistan vacc.,<br>Nigeria cVDPV http://promedmai=
l.org/post/20230209.8708270=0D<br>Poliomyelitis update (07): WPV1 ES, cVDPV=
2 AFP & ES, lab accident,<br>PHEIC http://promedmail.org/post/20230206.8708=
199=0D<br>Poliomyelitis update (06): WPV1 ES, cVDPV1 AFP, cVDPV2 ES<br>http=
://promedmail.org/post/20230128.8708021=0D<br>Poliomyelitis update (05): WP=
V1 ES, cVDPV1 AFP, cVDPV2 AFP & ES,<br>Pakistan http://promedmail.org/post/=
20230121.8707867=0D<br>Poliomyelitis update (04): cVDPV1 (Congo DR), cVDPV2=
 AFP (Congo DR),<br>ES (USA) http://promedmail.org/post/20230114.8707785=0D=
<br>Poliomyelitis update (03): USA, wastewater cVDPV2, comment<br>http://pr=
omedmail.org/post/20230107.8707675=0D<br>Poliomyelitis update (02): WPV1 ES=
, cVDPV1 AFP & ES, cVDPV2 AFP & ES,<br>violence http://promedmail.org/post/=
20230106.8707649=0D<br>Poliomyelitis update (01): (Canada) VDPV2, wastewate=
r, RFI<br>http://promedmail.org/post/20230102.8707576]<br>.................=
................................sb/jh/rd/jh<br></body>
</html><!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>*##########################################################*<br>*****=
*******************************************************<br>ProMED makes eve=
ry effort to verify the reports that are posted, but the accuracy<br>and co=
mpleteness of the information, and of any statements or opinions based<br>t=
hereon, are not guaranteed. The reader assumes all risks in using informati=
on<br>posted or archived by ProMED. ISID and its associated service provide=
rs shall not<br>be held responsible for errors or omissions or held liable =
for any damages incurred<br>as a result of use or reliance upon posted or a=
rchived material.<br>******************************************************=
******<br>Donate to ProMED. Details available at: https://isid.networkforgo=
od.com/projects/79924-invest-in-the-mission.<br>***************************=
*********************************<br>Visit ProMED's website at https://www.=
promedmail.org/.<br>Submit all items for posting via the ProMED website at =
https://promedmail.org/submitinfo/.<br>If you have any questions or need su=
pport, please contact us via the ProMED website at  https://promedmail.org/=
support/.<br>You may subscribe/unsubscribe at  https://isid.org/promedmail-=
subscribe/.<br><div><a href=3D"https://u19268662.ct.sendgrid.net/asm/?user_=
id=3D19268662&amp;data=3DLXvVLDWaFqks7F84kVhbZv1RbgC8a-M4Gw_AZmp73XRoMDAwdT=
AwMG8RGa6HifCjMFmBa5gS5T-vQVAOto4iMtefdjS45lpmq0A7TNP3W8hF1zo--lBkaokq7sqyX=
7l6eoF8M4saL8Eia_zdvCxLKOfeespfxmWY4h9ggCdBNW8cSFRGBWlLA90K8RR4j9SKQ3h0-QHp=
GnNGBhw3Zf44By9G3xTQBGuZ_AJwBntxCPVB1bbDY-ICfpZwEmXrAMETN0cXJ-uTqybfsMDz4CW=
OQbLT69FwCdaQB5DH6qdO2SaKiX_ohworry9VxK1qB76wYBGkTLFEa0vjZmX5vaZoyfI3B364bq=
Ap2wSBUlOEXclCcxJz9cOzAkSiARe5kjurjszMUIMZ_f_gax36G6Kcy4K7WF_bLxdzISqwg0u3m=
PCES4FbundtHt2iwdlZlARY4zWk8xAYrvuwhyjCBo25VTHFTJzSseFo3x3WG8P59w9YVH0AYv2B=
xhEOhfOyCA-BYJIciMtiJ-cGzLMI4mpk6y1fpAdF6yh8DS_jqw0pLBD-A6RwCb_U42sRmBEEfY1=
Xp-mEE6dKoQlYZq2vclOCHaaglB_1cQACsnMHv86NpnifATf2KFNol7XMG1OVT5DBhA50GKq2HQ=
SCFdCnsjCMjWbrScxkMKsIUroCbn-2w8tmWAsw7bcph26LpdkTy14bq0ZlaIRjE9wuR_Nx3Tupv=
dn-X9zAYz4oK8ItCUpnagP8dEHb3RlNiZhngdGd84Pbm8avYmd7HRTdxJTgOlQGkXjHhnt-zeY-=
bQl6erlj7ukKWTtxIz_M6iZn_KJ2dsW0Pll7-HnHscTF5Uk8C0AGxGtc7Fa8LfV8EN1-PpGZPcr=
G_qB3lEePzU26KQoOq3CRao0r2cnOZTXkYJ1TwLEJD5y3ChDHMHPb9FQpiEtuM5rsOQnObPUlb7=
Qx7zlBZP_5ToRr-ydp6CrnF1yK6qaBF2ccwYnzA7gOe7zu9Ldpy5ZvIp65G5LPvA7vIfK5bqsCo=
lFx0kgLhE949xtwM_wGnIVk9aAe72Z3aCMvRAzZ_A19jMsbzfePk853P3RRxnJuAhx4iq_3zQpD=
ugfxcGnw5lX4tA6ESRHAFweu-irQxgtpjetvEFi4NS3RuNtIQIeu8VCrE7LNCCzpBLJ9pqPtCex=
1QYIPjZFKbZZ4JahhE7drS9iEYRyv--1CUzhUePzpNko3yHkMqas=3D" target=3D"_blank" =
class=3D"Unsubscribe--unsubscribePreferences" style=3D"font-family:sans-ser=
if;text-decoration:none;">Unsubscribe Preferences</a></div><br>############=
################################################<br>#######################=
#####################################<br><br><img src=3D"https://u19268662.=
ct.sendgrid.net/ss/o/LbtalBvHhFtzyiegKfBhew/430/hjaIV4s9SICUbHTyxfVmcA/ho.g=
if" alt=3D"" width=3D"1" height=3D"1" border=3D"0" style=3D"height:1px !imp=
ortant;width:1px !important;border-width:0 !important;margin-top:0 !importa=
nt;margin-bottom:0 !important;margin-right:0 !important;margin-left:0 !impo=
rtant;padding-top:0 !important;padding-bottom:0 !important;padding-right:0 =
!important;padding-left:0 !important;"/></body>
</html>
--d2158366cbaedbb68e23c276c250a630374bbc9876fec343b37c8787761f--
